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Inadequate HIV care after incarceration: case closed
At any given moment, one in 99 adults in the USA 
are behind bars in prisons and jails, often for offenses 
related to the use or sale of illicit substances.1 This mass 
incarceration overwhelmingly affects racial and ethnic 
minority men; the lifetime risk of incarceration is more 
than 30% for African-American men, compared with 
17% for white men.2 Drug laws that strictly penalise 
the possession, use, and sale of illicit substances, and 
the less overt targeting of minorities for search and 
arrest, have led to people with HIV infection also being 
disproportionately incarcerated. 
Most metrics show that HIV care in US prisons is 
adequate; in jails, where lengths of stay are typically 
short and local budgets are typically meager, the quality 
of HIV care is more variable. However, after release, 
former inmates often have loss of viral suppression or 
loss of medical care.3–5 In their Article in The Lancet HIV,6 
Kelsey B Loeliger and colleagues add a weighty analysis 
to the mounting evidence on the perils of release 
from incarceration for people with HIV. By linking ad-
ministrative and medical databases maintained by the 
Connecticut state correctional system with state public 
health authority data on community-based testing for 
HIV, Loeliger and colleagues assessed linkage to care after 
release from prisons and jails between 2007 and 2014, 
using viral load measurements as a proxy for engagement 
in HIV care. 
The authors found low rates of linkage to care in the 
weeks just after release, when the antiretroviral supply 
provided by correctional facilities would run out, and 
viral load tests were done within 30 days of release in 
only a third of post-release periods. Encouragingly, 
evidence of engagement in HIV care increased over 
time; 76% of releases had a viral load drawn within 
6 months after release. However, a substantial 
proportion had detectable viral loads of HIV. Factors 
independently associated with linkage to care within 
30 days of release included intermediate incarceration 
duration (31–364 days), receipt of transitional case 
management, diagnosis with two or more comorbidities, 
and treatment with antiretroviral therapy during 
incarcer ation. 
This report has several important limitations, 
including those that are inherent to the reliance on 
data sources that might be incomplete and the use of 
an imperfect surrogate for actual visitation to a HIV 
care provider. However, the findings are similar to that 
of previous reports and highlight that the HIV/AIDS 
strategy in the USA is negligent and inadequate, given 
the consequences that a fumbled transition of HIV 
care after release from prison and jail could have for 
individual and public health.
In addition to the risk of CD4 cell depletion and 
immunosuppression, breaks in HIV therapy lead to a 
rebound in viraemia, and deleterious immune activation 
and inflammatory responses.7 The discontinuation of 
antiretrovirals in the SMART trial of treatment inter-
ruption guided by CD4 cell count was associated with all-
cause mortality and opportunistic conditions.8 Because 
of the risks associated with viral rebound, studies 
involving analytic treatment interruption now have 
safety measures to limit the magnitude and duration of 
viraemia. 
Equally concerning is the potential loss of viral 
suppression after release, which could lead to an in-
creased risk of transmission of HIV to other people.9 
A return to sexual and injection behaviours that risk viral 
transmission, coupled with loss of viral suppression will 
contribute to the spread of HIV in communities that 
are affected disproportionately by sexually transmitted 
infections, substance use, and incarceration. 
The authors also found, but do not stress, that even 
during the relatively controlled setting of incarceration, 
the proportion of incarceration periods that involved 
treatment with antiretrovirals was low, and the 
proportion that achieved viral suppression was even 
lower. Although rates of both of these factors improved 
over time, only 56·3% of the releases during 2013–14 
had an undetectable viral load before release. Notably, 
this finding suggests access and utilisation of HIV 
therapy in correctional settings remains suboptimal, 
particularly because of the reported association between 
subsequent linkage to care and the receipt of HIV 
therapy during incarceration. 
The authors, like others, suggest ways to solve the 
inadequacy of post-release care, including real-time 
use of public health surveillance data to identify and 
intervene with those out of care (ie, Data to Care)10 and 
broader use of case management type services. Data 
to Care is an important public health tool; however, 
it primarily acts as a safety net designed to catch those 
who fall out of care. Case management is a pragmatic and 
attractive upstream intervention but, its effectiveness 
in linking people with HIV to care and promoting viral 
suppression is unclear, and even in studies with positive 
findings, effects have been modest.11,12 
The intransigence of the break in the continuum of 
HIV care when inmates transition from incarceration 
to the community—despite approaches such as case 
management and motivational interventions—shows 
that structural barriers hinder successful community 
reintegration after release from prison or jail. Poverty 
and food insecurity, untreated substance use and men-
tal health disorders, racial and ethnic discrimination, 
and other prevalent social factors, are inadequately 
addressed by even the most thoughtfully designed 
individual-level interventions. Recognition of these social 
factors, including mass incarceration itself, as being toxic 
and unacceptable will spur on the policy changes that are 
needed to bridge this tragic gap in HIV care. 
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